All Type of News
Heartbroken patients even with extension of the Soliris benefit
The health insurance standard of ‘Soliris (eculizumab)’, the only domestic PHN (paroxismal nocturnal hemoglobinuria) treatment, has been extended since the 1st. Now, patients who are pregnant up to 3 months after chil...
Pharmaceutical companies spent the most in biotechnology as their R&D expenses
The section that spent the most expenses in research courses was observed to be the technological field for biotechnology.
The Korea Health Industry Development Institute unveiled the analysis result of research expe...
The HIRA decided to reorganize the Drug Reimbursement Evaluation Committee due to the Xalkori’s lobbying incident
The Health Insurance Review & Assessment Service (HIRA), embarrassed by the Xalkori’s lobbying incident, decided to reorganize the Drug Reimbursement Evaluation Committee (DREC).
The purpose of the reorganization is ...
AstraZeneca asked for code of ethics to pharmaceutical distribution companies
It is noticed that AstraZeneca requested application of ethics code to its trading pharmaceutical distribution companies.
According to the industry concerned on the 6th, AstraZeneca distributed questionnaire of ethic...
Huons sells ‘Nicorett’ to enter the antismoking treatment marketHuons, a pharmaceutical company listed in KOSDAQ, entered the antismoking treatment market.
Huons (CEO Jae-gap Jeon) and Johnson & Johnson Korea unveiled on the 6th that they s...
|
Series of partnerships with multinational pharmaceutical companies
Not will everyone who tries achieve a result. The business keyword of 2015 in the domestic pharmaceutical industry is definitely the ‘Global Expansion’. Many companies are challenging towards the goal, but few compani...
26 multinational pharmaceutical companies spent KRW 21 billion on social contribution in 2014
It is observed that multinational pharmaceutical companies spend 0.44% of their sales on social contribution funds in 2014.
According to the survey titled the ‘Current State in Social Contributions of Multinational P...
Fillers and Botulinum Toxin become major with their KRW 200 billion market
As entering the KRW 200 billion level, the market of fillers and Botulinum Toxin rises as one of the major markets.
According to the pharmaceutical industrial report revealed recently by Hana Daetoo Securities, the s...
The most prescribed pharmaceutical product for the Patent Linkage System is ‘Januvia’
After the enforcement of the Patent Linkage System, it is known that diabetes treatments, Januvia and Janumet, are the original products that generic companies are keeping their eyes on.
According to the informed pha...
The prescription rate of Champix in antismoking treatments was 72.1% “patient-sharing medical costs are excessive”
It is known that 7 of 10 patients prescribed antismoking treatments as a part of the Smoking Cessation Supporting Project that has been conducted since the last February were prescribed ‘Champix’.
According to Assemb...
